Potential prescribing issues among older HIV-infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern?
HIV/AIDS
antiretrovirals
medication errors
patient safety
prescribing
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
09
05
2020
revised:
23
06
2020
accepted:
09
07
2020
pubmed:
28
8
2020
medline:
27
7
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
To determine the prevalence of potential prescribing issues (PPI) in HIV-infected subjects aged ≥65 years according to the Beers and STOPP/START criteria and antiretroviral drug-drug interactions (Liverpool website). Secondary objectives were to assess the concordance between Beers and STOPP/START criteria in our population, and to identify the drugs most frequently involved in PPI. Cross-sectional cohort study based on a systematic review of the electronic drug prescriptions confirmed by an interview of 91 HIV-infected patients aged ≥65 years. Discrepancies between prescription criteria were assessed using crosstabs and compared using the χ The mean age was 72.1 (5.6) years, 75.8% had ≥3 comorbidities and 59.3% polypharmacy. PPI were identified in 87.9%: 71.4% by STOPP/START and 45.1% by Beers. Comparing both criteria, 56.9% of PPI by STOPP/START were detected by Beers, while 92.5% of those detected by the Beers criteria were detected by STOPP/START (P < .001). Amber/red flag interactions between antiretrovirals and comedications were found in 45.1%: 3 severe (red) in 2 patients (2.2%). The most frequent drugs involved in PPI were benzodiazepines (>30%). Cobicistat was the drug most frequently involved in potential interactions (42.2%). The prevalence of PPI among older HIV-infected persons gives cause for concern, as it is almost 90%. Optimization strategies, including a critical review of the treatment plan, should be implemented in clinical routine by a multidisciplinary team, in particular in patients with multiple comorbidities and polypharmacy. The STOPP/START criteria seem to detect more PPI, mainly for European populations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1310-1317Informations de copyright
© 2020 The British Pharmacological Society.
Références
O'Connor MN, Gallagher P, O'Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012;29(6):437-452.
Fu AZ, Jiang JZ, Reeves JH, Fincham JE, Liu GG, Perri M III. Potentially inappropriate medication use and healthcare expenditures in the US community-dwelling elderly. Med Care. 2007;45(5):472-476.
Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging. 1999;14(2):141-152.
Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Div Geriatr Med. 1991;151(9):1825-1832.
Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med. 1997 Jul;157(14):1531-1536.
Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003 Dec8-22;163(22):2716-2724.
Rancourt C, Moisan J, Baillargeon L, Verreault R, Laurin D, Grégoire JP. Potentially inappropriate prescriptions for older patients in long-term care. BMC Geriatr. 200415;4:9. https://doi.org/10.1186/1471-2318-4-9
Holt S, Schmeidl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31-32):543-551.
Rognstad S, Brekke M, Fetveit A, Spigset O, Wyller TB, Straand J. The Norwegian general practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients: a modified Delphi study. Scand J Prim Health Care. 2009;27(3):153-159.
Fick D, Semla T, Beizer J, et al. The American Geriatrics Society 2012 Beers criteria update expert panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. Jags. 2012;60(4):616-631. https://doi.org/10.1111/j.1532-5415.2012.03923.x [online]
Hamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171(11):1013-1019.
Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (screening tool of older Persons' prescriptions) and START (screening tool to alert doctors to right treatment): consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72-83.
Delgado Silveira E, Muñoz García M, Montero Errasquin B, Sánchez Castellano C, Gallagher PF, Cruz-Jentoft AJ. Inappropriate prescription in older patients: the STOPP/START criteria. Rev Esp Geriatr Gerontol. 2009;44(5):273-279.
O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-218.
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227-2246.
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society Beers criteria update expert panel. American Geriatrics Society 2019 updated AGS Beers criteria® for potentially inappropriate medication use in older adults. J am Geriatr Soc. 2019;67(4):674-694.
Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77(1):201-210.
Motl S, Timpe E, Eichner S. Proposal to improve MedWatch: decentralized, regional surveillance of adverse drug reactions. Am J Health Syst Pharm. 2004;61(17):1840-1842.
Blozik E, Born AM, Stuck AE, Benninger U, Gillmann G, Clough-Gorr KM. Reduction of inappropriate medications among older nursing-home residents: a nurse-led, pre/post-design, intervention study. Drugs Aging. 2010;27(12):1009-1017.
Dunn RL, Harrison D, Ripley TL. The beers criteria as an outpatient screening tool for potentially inappropriate medications. Consult Pharm. 2011;26(10):754-763.
Thomas RE, Thomas BC. A systematic review of studies of the STOPP/START 2015 and American geriatric society Beers 2015 criteria. Curr Aging Sci. 2019;2:121-154.
Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61-68.
Smi M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810-818.
Ware D, Palella FJ Jr, Chew KW, et al. Prevalence and trends of polypharmacy among HIV-positive and negative men in the multicenter AIDS cohort study from 2004 to 2016. PLoS ONE. 2018;13(9):e0203890. https://doi.org/10.1371/journal.pone.0203890
Guaraldi G, Malagoli A, Calcagno A, et al. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65-74 years and more than 75 years. BMC Geriatr. 2018;18(1):99. https://doi.org/10.1186/s12877-018-0789-0
Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130-1139.
Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787-1797.
Greene M, Steinman MA, McNicholl IR, Valcour VJ. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. Am Geriatr Soc. 2014;62(3):447-453.
McNicholl IR, Gandhi M, Hare CB, Greene M, Pierluissi E. A pharmacist- led program evaluate and reduce polypharmacy and potentially InappropriatePrescribing in older HIV-positive patients. Pharmacotherapy. 2017;37(12):1498-1506.
Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-83;17(1):37-49.
Martínez de la Iglesia J, Onís Vilches Mª C, Dueñas Herrero R, Albert Colomer C, Aguado Taberné C, Luque Luque R. Versión española del cuestionario de Yesavage abreviado (GDS) para el despistaje de depresión en mayores de 65 años: adaptación y validación. Medifam. 2002;12(10):26-40.
Wu AWZ, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786-798.
Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243-1250.
Rami L, Valls-Pedret C, Bartrés-Faz D, et al. Cuestionario de reserva cognitiva. Valores obtenidos en población anciana sana y con enfermedad de Alzheimer. Revista de Neurología. 2011;52(4):195-201.
Courlet P, Livio F, Guidi M, Swiss HIVCohort Study. Polypharmacy, drug-drug interactions, and inappropriate drugs: new challenges in the aging population with HIV. Open Forum Infect Dis. 201921;6(12):ofz531. https://doi.org/10.1093/ofid/ofz531
Blanco JR, Morillo R, Abril V, et al. Deprescribing of non-antiretroviral therapy in HIV-infected patients. Eur J Clin Pharmacol. 2020;76(3):305-318.
Negredo E, Back D, Blanco JR, et al. Aging in HIV-infected subjects: a new scenario and a new view. Biomed Res Int. 2017;2017:5897298. https://doi.org/10.1155/2017/5897298
Scott LJ. Dolutegravir/lamivudine single-tablet regimen: a review in HIV-1 infection. Drugs. 2020;80(1):61-72.
van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to Dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a Tenofovir Alafenamide-based three- or four-drug regimen for maintenance of Virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO study. Clin Infect Dis. 2020pii;ciz1243. https://doi.org/10.1093/cid/ciz1243
Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. Drugs. 20182;10:215-224. 2018 Nov;78(16):1741-1750
Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019;6(9):e576-e587.
Nozza S, Malagoli A, Maia L, et al. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. J Antimicrob Chemother. 2017;72(10):2961. https://doi.org/10.1093/jac/dkx282
Livio F, Marzolini C. Prescribing issues in older adults living with HIV: thinking beyond drug-drug interactions with antiretroviral drugs 2019; 10: 2042098619880122.